These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27894813)

  • 1. Salicylic acid retention impairs aspirin reactivity in type 2 diabetes.
    Zhang H; Xie H; Zheng X; Chai Y; Tang Z; Chen H; Li F; Christoph H; Chen J; Sun W; Ye H; Wang S; Hao H; Chen X
    Eur J Pharmacol; 2017 Jan; 794():234-245. PubMed ID: 27894813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients.
    Postula M; Janicki PK; Rosiak M; Przybylkowski A; Kaplon-Cieslicka A; Grygorowicz T; Trzepla E; Filipiak KJ; Czlonkowski A; Opolski G
    Cardiol J; 2013; 20(2):170-7. PubMed ID: 23558875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the influence of the interaction between acetylsalicylic acid and salicylic acid on platelet function in whole blood and isolated platelets: influence of neutrophils.
    González-Correa JA; Muñoz-Marín J; López-Villodres JA; Navas MD; Guerrero A; Torres JA; De La Cruz JP
    Pharmacol Res; 2007 Aug; 56(2):168-74. PubMed ID: 17644353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin sensitivity of platelet aggregation in diabetes mellitus.
    Albert SG; Hasnain BI; Ritter DG; Joist JH; Mooradian AD
    Diabetes Res Clin Pract; 2005 Nov; 70(2):195-9. PubMed ID: 15894396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment.
    Temperilli F; Rina A; Massimi I; Montemari AL; Guarino ML; Zicari A; Pulcinelli FM
    Platelets; 2015; 26(8):783-7. PubMed ID: 25734355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation.
    Patrick J; Dillaha L; Armas D; Sessa WC
    Postgrad Med; 2015 Aug; 127(6):573-80. PubMed ID: 25998572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salicylamide reverses the aspirin-antagonistic effect of salicylic acid on rat platelet cyclooxygenase.
    Rizk M; Abdel-Rahman MS
    Prostaglandins Leukot Essent Fatty Acids; 1994 Nov; 51(5):363-7. PubMed ID: 7846108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
    Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
    Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
    Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
    Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actions and interactions of acetylsalicylic acid, salicylic acid and diflunisal on platelet aggregation.
    Nitelius E; Brantmark B; Fredholm B; Hedner U; Forshell GP; Wåhlin-Boll E; Melander A
    Eur J Clin Pharmacol; 1984; 27(2):165-8. PubMed ID: 6499897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
    Capodanno D; Patel A; Dharmashankar K; Ferreiro JL; Ueno M; Kodali M; Tomasello SD; Capranzano P; Seecheran N; Darlington A; Tello-Montoliu A; Desai B; Bass TA; Angiolillo DJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):180-7. PubMed ID: 21386092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.
    Santilli F; Davì G; Consoli A; Cipollone F; Mezzetti A; Falco A; Taraborelli T; Devangelio E; Ciabattoni G; Basili S; Patrono C
    J Am Coll Cardiol; 2006 Jan; 47(2):391-7. PubMed ID: 16412866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acetylsalicylic acid on human platelet function in vivo at salicylate steady state.
    Simrock R; Missalla A; Schwidtal P; Lischke V; Breddin HK
    Thromb Haemost; 1984 Apr; 51(2):269-71. PubMed ID: 6740559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of aspirin-triggered lipoxin A4, aspirin, and salicylic acid in the modulation of the oxidative and inflammatory responses induced by plasma from women with pre-eclampsia.
    Gil-Villa AM; Alvarez AM; Velásquez-Berrío M; Rojas-López M; Cadavid J AP
    Am J Reprod Immunol; 2020 Feb; 83(2):e13207. PubMed ID: 31696583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo.
    Jespersen B; Thiesson HC; Henriksen C; Therland K; Falk C; Poulsen T; Fogh B; Madsen K; Walther S; Jensen BL
    Nephrol Dial Transplant; 2009 May; 24(5):1644-55. PubMed ID: 19193738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lack of aspirin resistance in patients with coronary artery disease.
    Homoródi N; Kovács EG; Leé S; Katona É; Shemirani AH; Haramura G; Balogh L; Bereczky Z; Szőke G; Péterfy H; Kiss RG; Édes I; Muszbek L
    J Transl Med; 2016 Mar; 14():74. PubMed ID: 26980433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.
    Kapłon-Cieślicka A; Rosiak M; Postuła M; Serafin A; Kondracka A; Opolski G; Filipiak KJ
    Kardiol Pol; 2013; 71(9):893-902. PubMed ID: 24065375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.
    Kobzar G; Mardla V; Samel N
    Platelets; 2011; 22(5):338-44. PubMed ID: 21557683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet aggregation and endothelial protection of I4, a new synthetic anti-diabetes sulfonylurea compound.
    Ma L; Lu N; Wu G
    Platelets; 2015; 26(4):342-8. PubMed ID: 24832568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.